Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to develop the first immune therapy eye drops to prevent the long-term ...

Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of ...

European shares struggle ahead of speeches from ECB policymakers 9:30 AM UTC Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after ...